#USA #Houston #AI-Driven Drug Discovery #Sino Biological #4RISE™

The Future of Drug Discovery: Sino Biological Launches 4RISE™

In the rapid world of biopharmaceutical development, time is a precious commodity. Recognizing this, Sino Biological, Inc. has introduced its latest innovation, 4RISE™, a cutting-edge service designed specifically for the validation of AI-developed protein binders. Launched on November 13, 2026, in Houston, 4RISE™ aims to accelerate the pace of drug discovery by integrating advanced technology into wet-lab practices.

The Need for Speed

AI-designed protein binders play a crucial role in identifying and treating various diseases. However, these innovative solutions require rigorous laboratory validation to confirm their effectiveness. 4RISE™ addresses this need by providing high-throughput services that ensure the target-binding activity of these protein candidates can be validated swiftly and accurately.

Utilizing Sino Biological's proprietary XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform, the service can produce recombinant proteins in as little as three hours, boasting a success rate exceeding 99%. This efficiency allows researchers to quickly synthesize a variety of protein formats, from small proteins to complex enzymes, supporting faster experimental testing and enabling timely feedback for refining designs.

A Seamless Workflow with Real-Time Data

Through state-of-the-art tools like Carterra High-Throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ offers comprehensive binding screening and kinetic analysis, facilitating an extensive understanding of protein interactions. In just three days, clients receive AI-ready binding data, with structured datasets accessible through a real-time API. This streamlined access ensures that researchers have the vital information needed for further analysis and subsequent experiments without unnecessary delays.

Tailored Solutions for Diverse Needs

Understanding the complexities of modern research, 4RISE™ incorporates flexible workflows tailored to different candidate formats and validation goals. The service offers:

• - Rapid Hit Discovery: Depending on prior screenings, this ensures quick identification of binding-positive mini-proteins and VHHs.
• - Comparative Binder Screening: This evaluates purified candidates under standardized conditions, assisting in the prioritization of the most promising targets.
• - Affinity Kinetic Characterization: Provides critical quantitative insights into binding interactions, essential for selecting lead structures.

Additionally, 4RISE™ also offers more than 20 development assays, over 1,000 protein bioactivity assays, and over 10 cell-based functional assays, which significantly enhance the evaluation and optimization of candidates.

Proven Track Record of Excellence

Sino Biological, a recognized leader in recombinant technology, has been collaborating with AI firms to validate AI-driven antibody development and protein engineering projects in laboratory settings. The lab's credibility is further underscored by numerous studies supporting this validation, published in prestigious journals such as Science, Nature Communications, and Scientific Reports.

Dr. Rob Burgess, the CEO of Sino Biological US, remarked, “AI-designed molecules require reliable experimental evidence from the lab to demonstrate their potential.” With 4RISE™, researchers can quickly assess candidates, shorten development timelines, and transition promising discoveries into tangible applications.

Explore the Future of Drug Discovery

As the demand for rapid and effective drug development continues to grow, Sino Biological’s 4RISE™ stands at the forefront, offering indispensable services that cater to the evolving landscape of biopharmaceutical research. Dive into the future of AI-driven drug discovery with 4RISE™ and ensure your research stays ahead in the race to find new therapeutic solutions.

Explore the services of 4RISE™ and see how they can transform your drug development process at www.sinobiological.com.